Shares of Target Co. (NYSE:TGT – Get Rating) have been assigned an average rating of “Moderate Buy” from the twenty-eight research firms that are currently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $190.42.
Several analysts have recently commented on TGT shares. DA Davidson lowered their price objective on Target from $205.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday, June 8th. Deutsche Bank Aktiengesellschaft decreased their price target on Target from $227.00 to $198.00 and set a “buy” rating for the company in a research report on Wednesday, June 8th. Raymond James decreased their price target on Target from $205.00 to $190.00 and set a “strong-buy” rating for the company in a research report on Wednesday, June 8th. Barclays decreased their price target on Target from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, June 8th. Finally, Guggenheim reduced their price objective on Target from $225.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, June 8th.
Insider Transactions at Target
In other news, insider John J. Mulligan sold 45,490 shares of the business’s stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $139.98, for a total transaction of $6,367,690.20. Following the transaction, the insider now directly owns 157,333 shares of the company’s stock, valued at $22,023,473.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.29% of the company’s stock.
Institutional Inflows and Outflows
Target Stock Up 2.5 %
Shares of Target stock opened at $163.38 on Thursday. Target has a one year low of $137.16 and a one year high of $268.98. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.87 and a quick ratio of 0.14. The stock’s 50-day moving average is $151.12 and its 200 day moving average is $194.79. The firm has a market cap of $75.76 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 1.76 and a beta of 1.00.
Target (NYSE:TGT – Get Rating) last announced its quarterly earnings results on Wednesday, May 18th. The retailer reported $2.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($0.81). The firm had revenue of $24.83 billion during the quarter, compared to the consensus estimate of $24.48 billion. Target had a return on equity of 44.75% and a net margin of 5.48%. The firm’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.69 EPS. Equities research analysts anticipate that Target will post 8.7 EPS for the current year.
Target Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Saturday, September 10th. Stockholders of record on Wednesday, August 17th will be issued a $1.08 dividend. The ex-dividend date is Tuesday, August 16th. This represents a $4.32 annualized dividend and a dividend yield of 2.64%. This is an increase from Target’s previous quarterly dividend of $0.90. Target’s payout ratio is currently 29.85%.
Target Company Profile
Target Corporation operates as a general merchandise retailer in the United States. The company offers food assortments, including perishables, dry grocery, dairy, and frozen items; apparel, accessories, home décor products, electronics, toys, seasonal offerings, food, and other merchandise; and beauty and household essentials.
- Get a free copy of the StockNews.com research report on Target (TGT)
- Procter’s Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Target Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Target and related companies with MarketBeat.com's FREE daily email newsletter.